Gastrointestinal cancer is the fastest-growing early-onset cancer in the US, research shows
Colorectal cancer was the most common early-onset gastrointestinal cancer in 2022, with over 20,800 diagnoses.
The rise in these cancers is largely attributed to modifiable risk factors, including obesity, poor diet, inactive lifestyles, smoking, and alcohol consumption.
The prognosis for early-onset gastrointestinal cancers is similar to or worse than later-onset cases, underscoring the need for improved prevention and early detection.
The American Cancer Society now recommends regular colorectal cancer screening from the age of 45, a reduction from the previous age of 50.
Dramatic rise in gastrointestinal cancers in people under 50
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
12 minutes ago
- Reuters
Texas judge dismisses Humana challenge to Medicare plan ratings
July 18 (Reuters) - A Texas federal judge dismissed a lawsuit brought by health insurer Humana (HUM.N), opens new tab challenging the U.S. Department of Health and Human Services' reduction in its star ratings for government-funded Medicare plans. Humana filed the lawsuit in September 2023 in the Northern District of Texas against the U.S. Department of Health and Human Services and former Health Secretary Xavier Becerra.
Reuters
12 minutes ago
- Reuters
National Consumer Alert on 7-OH Products Posing Significant Dangers
WASHINGTON, DC, July 18, 2025 (EZ Newswire) -- American Kratom Association (AKA), opens new tab is issuing a national consumer alert to warn consumers, retailers, and distributors of the serious health risks posed by products that contain dangerously high levels of 7-hydroxymitragynine (7-OH) — a powerful, highly psychoactive compound that is not naturally present in kratom leaf in any meaningful amount. The warning letters appropriately include 7-OH + pseudoindoxyl products that are an enhanced manipulation of the naturally occurring kratom compounds. The U.S. Food and Drug Administration (FDA) has recently issued multiple warning letters to companies selling these adulterated and illegal products, making it unequivocally clear: 7-OH products are unsafe, misleadingly marketed, and violate federal law. Why Consumers Should Be Concerned Retailers and Manufacturers Beware The AKA applauds the FDA's long-overdue action to protect consumers and remove these hazardous products from the marketplace. For years, AKA has advocated for commonsense regulations through state-level Kratom Consumer Protection Acts (KCPAs) that clearly prohibit dangerous alkaloid manipulation, including limits on 7-OH to no more than 2% of total alkaloid content—a threshold that corresponds with less than 1 mg per serving. What Consumers Can Do Additional Resources The Bottom Line: If it's not natural kratom, it's not kratom. About American Kratom Association (AKA) American Kratom Association (AKA) is a consumer-based, nonprofit organization, focused on furthering the latest science as guidance for kratom public policy. AKA works to give a voice to millions of Americans by fighting to protect their rights to access safe and natural kratom. For more information, visit and learn more at Media Contact Mac Haddowpress@ ### SOURCE: American Kratom Association (AKA) Copyright 2025 EZ Newswire See release on EZ Newswire
Reuters
an hour ago
- Reuters
Sarepta shares slump after third patient death this year
July 18 (Reuters) - Shares of Sarepta Therapeutics (SRPT.O), opens new tab declined 17% in early trading on Friday after a patient who had received one of the company's experimental gene therapies died, deepening investor concern over the use of its treatments. Sarepta said a 51-year-old man enrolled in an early-stage trial of gene therapy, SRP-9004, for the treatment of limb-girdle muscular dystrophy (LGMD) died from acute liver failure last month. This is the third death this year for Sarepta after two teenage boys who had received Elevidys, a gene therapy approved to treat a rare condition called Duchenne muscular dystrophy, died of liver failure. Sarepta said the patient was the last to be dosed in that study. LGMD includes a group of genetic disorders that primarily weaken the hip and shoulder muscles. The news of the death was first reported by pharma website BioCentury on Thursday evening. On Wednesday, Sarepta announced a restructuring plan that included 500 job cuts and halting development of several gene therapies for limb-girdle muscular dystrophy. It said then the cuts were a financial decision and that it hopes to find partners for these programs. The company said it plans to host a call with investors later on Friday.
